| Name | Title | Contact Details |
|---|
We hold market leading positions in advanced wound care, ostomy care, continence and critical care and infusion devices. Our customers depend on our advanced technologies to help reduce potential complications of skin breakdown and infection, and they rely on our products and services to help manage their conditions every day. Meeting their needs is what motivates us and is a source of tremendous pride for our nearly 9,500 employees who are based in more than 110 countries worldwide. At ConvaTec, we exist to improve the lives of the people we touch. We are committed to helping people with chronic health conditions lead the life they want – giving them more mobility, confidence and freedom. Our vision is to be recognised as the most respected and successful MedTech company, worldwide. To achieve this, we drive for excellence in all that we do – anticipating and addressing our customers` needs with advanced technologies and best-in-class products and services. Our values-based culture helps drive our success. Caring for People: We are passionate about improving people`s lives and put people at the centre of everything we do. Driving Innovation and Excellence: We are dedicated to finding innovative solutions that anticipate and address our customers` needs and to delivering best-in-class execution. Earning Trust: We earn trust by delivering quality products and services that our customers can rely on. Our personal actions underpin this trust – we do what we say we will do.
Companion Medical is a leader in the development of advanced technology to improve diabetes care. Companion`s InPen system is available in the U.S. and is the only FDA-cleared, smart insulin pen paired with an integrated diabetes management app.
Bronzini Dental Group is a Millbrae, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The merged expertise of SterilMed and The Scope Exchange in the repair and reprocessing of medical devices provides the opportunity to utilize a comprehensive single-source supplier. The merged expertise combined with SterilMed's broad market presence
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company`s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Approximately 1.7 million Americans have AAA, and the incidence of the condition increases with age. Endologix is currently marketing the AFX® Endovascular AAA System is available in the U.S., Europe, Latin America and other regions. The Nellix® EndoVascular Aneurysm Sealing System, a novel aneurysm sealing system, is approved for sale in Europe and other markets and for investigational use in the U.S. The Powerlink with IntuiTrak® Delivery System is available in Japan. These technologies are minimally invasive, allowing for greater patient comfort and quicker recovery compared to invasive surgical alternatives. Endologix products are protected by at least 52 U.S. patents with at least 956 allowed claims. Endologix is a publicly-held company trading on NASDAQ: ELGX. The Company`s corporate office is located in Irvine, California.